Verrica Pharmaceuticals (VRCA) EBIAT (2021 - 2025)
Historic EBIAT for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to -$274000.0.
- Verrica Pharmaceuticals' EBIAT rose 9880.14% to -$274000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$26.0 million, marking a year-over-year increase of 6939.21%. This contributed to the annual value of -$76.6 million for FY2024, which is 1430.55% down from last year.
- According to the latest figures from Q3 2025, Verrica Pharmaceuticals' EBIAT is -$274000.0, which was up 9880.14% from $204000.0 recorded in Q2 2025.
- Over the past 5 years, Verrica Pharmaceuticals' EBIAT peaked at $204000.0 during Q2 2025, and registered a low of -$24.8 million during Q3 2023.
- Moreover, its 5-year median value for EBIAT was -$10.2 million (2022), whereas its average is -$11.2 million.
- Its EBIAT has fluctuated over the past 5 years, first crashed by 2998192.77% in 2023, then soared by 10118.7% in 2025.
- Quarter analysis of 5 years shows Verrica Pharmaceuticals' EBIAT stood at -$9.5 million in 2021, then surged by 37.82% to -$5.9 million in 2022, then crashed by 314.94% to -$24.6 million in 2023, then soared by 34.18% to -$16.2 million in 2024, then skyrocketed by 98.31% to -$274000.0 in 2025.
- Its EBIAT stands at -$274000.0 for Q3 2025, versus $204000.0 for Q2 2025 and -$9.7 million for Q1 2025.